Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study Moskowitz, A. J., Advani, R. H., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Christian, B. A., Ansell, S. M., Moskowitz, C. H., Brown, L., Taft, D., Ansari, S., Zak, D. E., Sacchi, M., Manley, T., Herrera, A. F. AMER SOC HEMATOLOGY. 2019

View details for DOI 10.1182/blood-2019-122576

View details for Web of Science ID 000518218500563